ArticleeLife2020
Lipocalin-2 is an anorexigenic signal in primates.
Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The historical progression of positron emission tomography research in neuroendocrinology.Frontiers in neuroendocrinology · 2023Pooled it
- Biomaterials at the interface of bone-derived factors and inter-organ communication: Current evidence and future perspectives.Bioactive materials · 2026Review
- Lipocalin-2 perpetuates postoperative and post-infectious neuroinflammation and anxiety-like behavior.Brain, behavior, and immunity · 2026Article
- Bone as an endocrine regulator of lipid and energy metabolism.Reviews in endocrine & metabolic disorders · 2026Review
- The role of accessory proteins and co-factors in regulation of melanocortin-4 receptor signalling: An update.Journal of neuroendocrinology · 2026Review
- Endocrine Functions of Bone Are Suppressed by Orally Administered Glucose Regardless of Bodyweight.Clinical endocrinology · 2026Article
- Emerging roles of lipocalin-2-mediated neuroimmune interactions in chronic pain and itch.Frontiers in pharmacology · 2026Review
- Review
- Prospective changes in lipocalin-2 and adipocytokines among adults with obesity.Scientific reports · 2025Article
- Bone-derived factors mediate crosstalk between skeletal and extra-skeletal organs.Bone research · 2025Review
- Lipocalin-2 as a fundamental protein in type 2 diabetes and periodontitis in mice.Journal of periodontology · 2025Article
- Sex- and site-specific associations of circulating lipocalin 2 and incident colorectal cancer: Results from the EPIC cohort.International journal of cancer · 2025Article
- LCN2 blockade mitigating metabolic dysregulation and redefining appetite control in type 2 diabetes.Metabolic brain disease · 2025Article
- Novel secreted regulators of glucose and lipid metabolism in the development of metabolic diseases.Diabetologia · 2024Review
- Lipocalin 2-A bone-derived anorexigenic and β-cell promoting signal: From mice to humans.Journal of diabetes · 2024Review
- Correlation of lipocalin 2 and glycolipid metabolism and body composition in a large cohort of children with osteogenesis imperfecta.Journal of endocrinological investigation · 2024Article
- Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships.Research (Washington, D.C.) · 2024Article
- Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia.Journal of the Endocrine Society · 2023Article
- Evidence in Humans for Bone as an Endocrine Organ Regulating Energy Metabolism.Current opinion in endocrine and metabolic research · 2023Article
- Bifidobacterium longum supplementation improves age-related delays in fracture repair.Aging cell · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 5 institutions in 2 countries.
Funding
Abstract
In the mouse, the osteoblast-derived hormone Lipocalin-2 (LCN2) suppresses food intake and acts as a satiety signal. We show here that meal challenges increase serum LCN2 levels in persons with normal or overweight, but not in individuals with obesity. Postprandial LCN2 serum levels correlate inversely with hunger sensation in challenged subjects. We further show through brain PET scans of monkeys injected with radiolabeled recombinant human LCN2 (rh-LCN2) and autoradiography in baboon, macaque, and human brain sections, that LCN2 crosses the blood-brain barrier and localizes to the hypothalamus in primates. In addition, daily treatment of lean monkeys with rh-LCN2 decreases food intake by 21%, without overt side effects. These studies demonstrate the biology of LCN2 as a satiety factor and indicator and anorexigenic signal in primates. Failure to stimulate postprandial LCN2 in individuals with obesity may contribute to metabolic dysregulation, suggesting that LCN2 may be a novel target for obesity treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.